New cancer treatments show promise while health disparities persist in heart disease detection, and emerging links discovered between fertility issues and menopause timing

Two Phase 3 trials demonstrate significant breakthroughs in lung cancer treatment: sunvozertinib for EGFR exon 20 insertions and sacituzumab tirumotecan plus pembrolizumab for PD-L1-positive NSCLC both show substantial progression-free survival gains over current standard therapies.

Silent heart attacks and undiagnosed heart disease disproportionately affect deprived and ethnically diverse communities, with detection improving through primary care screening and social media outreach efforts.

Low-dose tamoxifen ('Baby TAM') proves effective in preventing breast cancer recurrence after DCIS, though its benefits vary significantly depending on whether patients are pre- or post-menopausal.

A new link identified between primary infertility and early menopause onset suggests women struggling with fertility experience natural menopause at younger ages than their fertile counterparts.

England reports the sharpest decline in sexually transmitted infection diagnoses in years, but concerning trends emerge with rising syphilis cases specifically among women.

Type 1 diabetes is independently associated with higher risk of subtrochanteric, femoral shaft, and hip fractures in a Danish population study, with age as a confounding factor.

Oral icotrokinra demonstrates high clearance rates and durable responses at high-impact psoriasis sites over one year with no additional adverse events compared to placebo.

In ANCA-positive vasculitis patients with severe kidney involvement, older age and low serum albumin levels at diagnosis independently predict long-term mortality outcomes.